Impact of cetirizine on the burden of allergic rhinitis

Eli O. Meltzer, J. Andrew Grant

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: The goals of this article include the reporting of the epidemiology, economic and medical impact of allergic rhinitis. In addition, the pharmacology and clinical profile of the therapeutic agent cetirizine are reviewed. Data sources: A detailed literature search was conducted. References are limited to the English language and human subjects and tissues. Studies considered relevant and important over the past 20 years are highlighted. Study selection: Prevalence and morbidity data were chosen from more recent assessments. Because cetirizine is a relatively new compound, studies from the past several years from peer-reviewed journals have been emphasized. Results: Allergic rhinitis affects between 15% and 25% of the US general population. It shares common pathophysiologic mechanisms with conjunctivitis and asthma and predisposes to nasal infections, otitis media, sinusitis, nasal polyposis, and orthodontic malocclusions. Direct medical care costs amount to up to 3 billion dollars every year. In addition, the quality of life of affected individuals is substantially compromised. Cetirizine is a potent H1-receptor antagonist and has anti-inflammatory properties. It does not interact with concomitantly administered medications, has no cardiac adverse effects, and does not appear to be associated with teratogenicity. Impairment of CNS function is comparable to other low- sedating antihistamines at the recommended dose of 10 mg daily for adults. Its clinical efficacy for allergic respiratory diseases has been established in numerous trials. Conclusions: Allergic rhinitis causes considerable suffering. Cetirizine, with a fine risk-benefit ratio, can be a most valuable therapeutic option.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalAnnals of Allergy, Asthma and Immunology
Volume83
Issue number5
StatePublished - Nov 1999

Fingerprint

Cetirizine
Nose
Histamine H1 Antagonists
Medical Economics
Histamine H1 Receptors
Conjunctivitis
Malocclusion
Clinical Pharmacology
Information Storage and Retrieval
Sinusitis
Otitis Media
Orthodontics
Psychological Stress
Health Care Costs
Epidemiology
Anti-Inflammatory Agents
Language
Asthma
Cross-Sectional Studies
Odds Ratio

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Impact of cetirizine on the burden of allergic rhinitis. / Meltzer, Eli O.; Grant, J. Andrew.

In: Annals of Allergy, Asthma and Immunology, Vol. 83, No. 5, 11.1999, p. 455-463.

Research output: Contribution to journalArticle

Meltzer, EO & Grant, JA 1999, 'Impact of cetirizine on the burden of allergic rhinitis', Annals of Allergy, Asthma and Immunology, vol. 83, no. 5, pp. 455-463.
Meltzer, Eli O. ; Grant, J. Andrew. / Impact of cetirizine on the burden of allergic rhinitis. In: Annals of Allergy, Asthma and Immunology. 1999 ; Vol. 83, No. 5. pp. 455-463.
@article{6b9bca676c634ddba0cbcbb4a0572efc,
title = "Impact of cetirizine on the burden of allergic rhinitis",
abstract = "Objective: The goals of this article include the reporting of the epidemiology, economic and medical impact of allergic rhinitis. In addition, the pharmacology and clinical profile of the therapeutic agent cetirizine are reviewed. Data sources: A detailed literature search was conducted. References are limited to the English language and human subjects and tissues. Studies considered relevant and important over the past 20 years are highlighted. Study selection: Prevalence and morbidity data were chosen from more recent assessments. Because cetirizine is a relatively new compound, studies from the past several years from peer-reviewed journals have been emphasized. Results: Allergic rhinitis affects between 15{\%} and 25{\%} of the US general population. It shares common pathophysiologic mechanisms with conjunctivitis and asthma and predisposes to nasal infections, otitis media, sinusitis, nasal polyposis, and orthodontic malocclusions. Direct medical care costs amount to up to 3 billion dollars every year. In addition, the quality of life of affected individuals is substantially compromised. Cetirizine is a potent H1-receptor antagonist and has anti-inflammatory properties. It does not interact with concomitantly administered medications, has no cardiac adverse effects, and does not appear to be associated with teratogenicity. Impairment of CNS function is comparable to other low- sedating antihistamines at the recommended dose of 10 mg daily for adults. Its clinical efficacy for allergic respiratory diseases has been established in numerous trials. Conclusions: Allergic rhinitis causes considerable suffering. Cetirizine, with a fine risk-benefit ratio, can be a most valuable therapeutic option.",
author = "Meltzer, {Eli O.} and Grant, {J. Andrew}",
year = "1999",
month = "11",
language = "English (US)",
volume = "83",
pages = "455--463",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "5",

}

TY - JOUR

T1 - Impact of cetirizine on the burden of allergic rhinitis

AU - Meltzer, Eli O.

AU - Grant, J. Andrew

PY - 1999/11

Y1 - 1999/11

N2 - Objective: The goals of this article include the reporting of the epidemiology, economic and medical impact of allergic rhinitis. In addition, the pharmacology and clinical profile of the therapeutic agent cetirizine are reviewed. Data sources: A detailed literature search was conducted. References are limited to the English language and human subjects and tissues. Studies considered relevant and important over the past 20 years are highlighted. Study selection: Prevalence and morbidity data were chosen from more recent assessments. Because cetirizine is a relatively new compound, studies from the past several years from peer-reviewed journals have been emphasized. Results: Allergic rhinitis affects between 15% and 25% of the US general population. It shares common pathophysiologic mechanisms with conjunctivitis and asthma and predisposes to nasal infections, otitis media, sinusitis, nasal polyposis, and orthodontic malocclusions. Direct medical care costs amount to up to 3 billion dollars every year. In addition, the quality of life of affected individuals is substantially compromised. Cetirizine is a potent H1-receptor antagonist and has anti-inflammatory properties. It does not interact with concomitantly administered medications, has no cardiac adverse effects, and does not appear to be associated with teratogenicity. Impairment of CNS function is comparable to other low- sedating antihistamines at the recommended dose of 10 mg daily for adults. Its clinical efficacy for allergic respiratory diseases has been established in numerous trials. Conclusions: Allergic rhinitis causes considerable suffering. Cetirizine, with a fine risk-benefit ratio, can be a most valuable therapeutic option.

AB - Objective: The goals of this article include the reporting of the epidemiology, economic and medical impact of allergic rhinitis. In addition, the pharmacology and clinical profile of the therapeutic agent cetirizine are reviewed. Data sources: A detailed literature search was conducted. References are limited to the English language and human subjects and tissues. Studies considered relevant and important over the past 20 years are highlighted. Study selection: Prevalence and morbidity data were chosen from more recent assessments. Because cetirizine is a relatively new compound, studies from the past several years from peer-reviewed journals have been emphasized. Results: Allergic rhinitis affects between 15% and 25% of the US general population. It shares common pathophysiologic mechanisms with conjunctivitis and asthma and predisposes to nasal infections, otitis media, sinusitis, nasal polyposis, and orthodontic malocclusions. Direct medical care costs amount to up to 3 billion dollars every year. In addition, the quality of life of affected individuals is substantially compromised. Cetirizine is a potent H1-receptor antagonist and has anti-inflammatory properties. It does not interact with concomitantly administered medications, has no cardiac adverse effects, and does not appear to be associated with teratogenicity. Impairment of CNS function is comparable to other low- sedating antihistamines at the recommended dose of 10 mg daily for adults. Its clinical efficacy for allergic respiratory diseases has been established in numerous trials. Conclusions: Allergic rhinitis causes considerable suffering. Cetirizine, with a fine risk-benefit ratio, can be a most valuable therapeutic option.

UR - http://www.scopus.com/inward/record.url?scp=0032754179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032754179&partnerID=8YFLogxK

M3 - Article

C2 - 10582731

AN - SCOPUS:0032754179

VL - 83

SP - 455

EP - 463

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 5

ER -